We treated 46 patients with multiple recurrent Clostridioides difficile infections (mrCDI) using a tapered-pulsed (T-P) fidaxomicin regimen, the majority of whom failed prior T-P vancomycin treatment. Sustained clinical response rates at 30 and 90 days were 74% (34/46) and 61% (28/46). T-P fidaxomicin shows promise for management of mrCDI.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciab233 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fidaxomicin versus oral vancomycin for infection among patients at high risk for recurrence based on real-world experience.
Infect Control Hosp Epidemiol
October 2024
Department of Medicine, Section of Infectious Diseases and Global Health, University of Chicago Medicine, Chicago, IL, USA.
Introduction: infection (CDI) is a common nosocomial infection and is associated with a high healthcare burden due to high rates of recurrence. In 2021 the IDSA/SHEA guideline update recommended fidaxomicin (FDX) as first-line therapy. Our medical center updated our institutional guidelines to follow these recommendations, prioritizing FDX use among patients at high risk for recurrent CDI (rCDI).
View Article and Find Full Text PDFManagement and Outcomes of Patients at a Specialty Clinic for Infection.
Open Forum Infect Dis
April 2024
George E Wahlen VA Hospital, Research Service, Salt Lake City, Utah, USA.
Vancomycin and fidaxomicin taper regimens were the most common treatment strategies employed but nearly half of patients (40/83) referred to our infection (CDI) clinic did not require further treatment. The overall 60-day CDI recurrence rate was 16.9% (11/65).
View Article and Find Full Text PDFIs shorter also better in the treatment of Clostridioides difficile infection?
J Antimicrob Chemother
June 2024
Department of Infectious Diseases, 3rd Faculty of Medicine, Charles University and University Hospital Bulovka, Budínova 67/2, 180 81, Praha 8, Prague, Czech Republic.
Objectives: To assess the effectiveness of shortened regimens of vancomycin or fidaxomicin in the treatment of Clostridioides difficile infection (CDI).
Methods: Adult patients with CDI hospitalized from January 2022 to May 2023 were included in this observational study. In patients with CDI treated with vancomycin or fidaxomicin, antibiotic treatment was discontinued after either 5 or 7 days of vancomycin or 5 days of fidaxomicin if there was a clinical response and improvement in laboratory parameters.
The effect of antibiotic therapy for Clostridioides difficile infection on mortality and other patient-relevant outcomes: a systematic review and meta-analysis.
Clin Microbiol Infect
January 2024
Infectious Diseases Institute, Rambam Health Care Campus, Haifa, Israel; Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
Background: Current practice guidelines favour fidaxomicin over vancomycin and exclude metronidazole from the recommended standard regimen for Clostridioides difficile infection (CDI), based on lower recurrence rates with fidaxomicin, giving little weight to mortality or the clinical implications of recurrences.
Objectives: To compile the effects of metronidazole, glycopeptides (vancomycin or teicoplanin), and fidaxomicin for CDI on mortality and other patient-relevant outcomes.
Data Sources: PubMed, the Cochrane Library, ClinicalTrials.
An insight into -associated diarrhea in Saudi children: diagnosis and treatment.
Expert Rev Gastroenterol Hepatol
November 2023
Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Article Synopsis
- Clostridioides difficile infection (CDI) is a common problem that can cause diarrhea in kids, especially after they take antibiotics.
- In Saudi Arabia, the way doctors diagnose and treat CDI in children is a bit different from international guidelines.
- Even though CDI isn't a big issue in Saudi hospitals, not all follow the recommended guidelines, which can lead to fewer cases being reported.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!